Advertisement

How Drugs Including Recreational Drugs Affect Asthma

  • Timothy E. Albertson
  • Kelly P. Owen
  • Mark E. Sutter
  • Nicholas J. Kenyon
Chapter

Abstract

Various drug and chemical exposures are associated with adverse effects on airways. These effects may induce or worsen the symptoms of asthma. The mechanisms of these airway changes vary from direct effects on receptors to immunologically mediated alterations.

Keywords

Recreational Drug Marijuana Smoke Acetaminophen Overdose Asthma Death Fatal Asthma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Leuppi, J.D., et al., Drug-induced bronchospasm: analysis of 187 spontaneously reported cases. Respiration, 2001. 68(4): p. 345–51.PubMedGoogle Scholar
  2. 2.
    Babu, K.S. and B.G. Marshall, Drug-induced airway diseases. Clin Chest Med, 2004. 25(1): p. 113–22.PubMedGoogle Scholar
  3. 3.
    Lunde, H., et al., Dyspnoea, asthma, and bronchospasm in relation to treatment with angiotensin converting enzyme inhibitors. BMJ, 1994. 308(6920): p. 18–21.PubMedGoogle Scholar
  4. 4.
    Wood, R., Bronchospasm and cough as adverse reactions to the ACE inhibitors captopril, enalapril and lisinopril. A controlled retrospective cohort study. Br J Clin Pharmacol, 1995. 39(3): p. 265–70.PubMedGoogle Scholar
  5. 5.
    Dykewicz, M.S., Cough and angioedema from angiotensin-converting enzyme inhibitors: new insights into mechanisms and management. Curr Opin Allergy Clin Immunol, 2004. 4(4): p. 267–70.PubMedGoogle Scholar
  6. 6.
    Kim, S.H. and H.S. Park, Pathogenesis of nonsteroidal antiinflammatory drug-induced asthma. Curr Opin Allergy Clin Immunol, 2006. 6(1): p. 17–22.PubMedGoogle Scholar
  7. 7.
    Martin-Garcia, C., et al., Safety of a cyclooxygenase-2 inhibitor in patients with aspirin-sensitive asthma. Chest, 2002. 121(6): p. 1812–7.PubMedGoogle Scholar
  8. 8.
    Kashiwabara, K. and H. Nakamura, Analgesic-induced asthma caused by 2.0% ketoprofen adhesive agents, but not by 0.3% agents. Intern Med, 2001. 40(2): p. 124–6.PubMedGoogle Scholar
  9. 9.
    El Miedany, Y., et al., Safety of etoricoxib, a specific cyclooxygenase-2 inhibitor, in asthmatic patients with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol, 2006. 97(1): p. 105–9.PubMedGoogle Scholar
  10. 10.
    Ruffin, R.E., et al., Assessment of beta-adrenoceptor antagonists in asthmatic patients. Br J Clin Pharmacol, 1982. 13(Suppl 2): p. 325 S-335 S.PubMedGoogle Scholar
  11. 11.
    Hanania, N.A., et al., The safety and effects of the beta-blocker, nadolol, in mild asthma: an open-label pilot study. Pulm Pharmacol Ther, 2008. 21(1): p. 134–41.PubMedGoogle Scholar
  12. 12.
    Salpeter, S.R., T.M. Ormiston, and E.E. Salpeter, Cardioselective beta-blockers in patients with reactive airway disease: a meta-analysis. Ann Intern Med, 2002. 137(9): p. 715–25.PubMedGoogle Scholar
  13. 13.
    Dickey, B.F., et al., beta-Adrenoceptor inverse agonists in asthma. Curr Opin Pharmacol, 2010. 10(3): p. 254–9.PubMedGoogle Scholar
  14. 14.
    Bond, R.A., et al., Getting to the heart of asthma: can “beta blockers” be useful to treat asthma? Pharmacol Ther, 2007. 115(3): p. 360–74.PubMedGoogle Scholar
  15. 15.
    Hanania, N.A., B.F. Dickey, and R.A. Bond, Clinical implications of the intrinsic efficacy of beta-adrenoceptor drugs in asthma: full, partial and inverse agonism. Curr Opin Pulm Med, 2010. 16(1): p. 1–5.PubMedGoogle Scholar
  16. 16.
    Lipworth, B.J. and P.A. Williamson, Beta blockers for asthma: a double-edged sword. Lancet, 2009. 373(9658): p. 104–5.PubMedGoogle Scholar
  17. 17.
    Grembiale, R.D., et al., Bronchial asthma induced by an antithyroid drug. Chest, 2001. 119(5): p. 1598–9.PubMedGoogle Scholar
  18. 18.
    Nguyen, L.T. and K.V. Luong, Propylthiouracil-induced asthma. Allergy, 2004. 59(8): p. 889–90.PubMedGoogle Scholar
  19. 19.
    Luong, K.V. and L.T. Nguyen, Hyperthyroidism and asthma. J Asthma, 2000. 37(2): p. 125–30.PubMedGoogle Scholar
  20. 20.
    Nakazawa, T. and S. Kobayashi, Influence of antithyroidal therapy on asthma symptoms in the patients with both bronchial asthma and hyperthyroidism. J Asthma, 1991. 28(2): p. 109–16.PubMedGoogle Scholar
  21. 21.
    Eneli, I., et al., Acetaminophen and the risk of asthma: the epidemiologic and pathophysiologic ­evidence. Chest, 2005. 127(2): p. 604–12.PubMedGoogle Scholar
  22. 22.
    Thomsen, S.F., et al., Intake of paracetamol and risk of asthma in adults. J Asthma, 2008. 45(8): p. 675–6.PubMedGoogle Scholar
  23. 23.
    Farquhar, H., et al., The role of paracetamol in the pathogenesis of asthma. Clin Exp Allergy, 2010. 40(1): p. 32–41.PubMedGoogle Scholar
  24. 24.
    Decramer, M., et al., Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary ­disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-­controlled trial. Lancet, 2005. 365(9470): p. 1552–60.PubMedGoogle Scholar
  25. 25.
    Rogers, D.F., Mucoactive agents for airway mucus hypersecretory diseases. Respir Care, 2007. 52(9): p. 1176–93; discussion 1193–7.Google Scholar
  26. 26.
    Sutherland, E.R., J.D. Crapo, and R.P. Bowler, N-acetylcysteine and exacerbations of chronic obstructive pulmonary disease. COPD, 2006. 3(4): p. 195–202.PubMedGoogle Scholar
  27. 27.
    Falliers, C.J. and A. Cato, Controlled trial of bronchodilator-mucolytic aerosols, combined and separate. Ann Allergy, 1978. 40(2): p. 77–83.PubMedGoogle Scholar
  28. 28.
    Bylin, G., et al., No influence of acetylcysteine on gas exchange and spirometry in chronic asthma. Eur J Respir Dis, 1987. 71(2): p. 102–7.PubMedGoogle Scholar
  29. 29.
    Ho, S.W. and L.J. Beilin, Asthma associated with N-acetylcysteine infusion and paracetamol poisoning: report of two cases. Br Med J (Clin Res Ed), 1983. 287(6396): p. 876–7.Google Scholar
  30. 30.
    Mant, T.G., et al., Adverse reactions to acetylcysteine and effects of overdose. Br Med J (Clin Res Ed), 1984. 289(6439): p. 217–9.Google Scholar
  31. 31.
    Zyoud, S.H., et al., Incidence of adverse drug reactions induced by N-acetylcysteine in patients with acetaminophen overdose. Hum Exp Toxicol, 2010. 29(3): p. 153–60.PubMedGoogle Scholar
  32. 32.
    Sandilands, E.A. and D.N. Bateman, Adverse reactions associated with acetylcysteine. Clin Toxicol (Phila), 2009. 47(2): p. 81–8.Google Scholar
  33. 33.
    Schmidt, L.E. and K. Dalhoff, Risk factors in the development of adverse reactions to N-acetylcysteine in patients with paracetamol poisoning. Br J Clin Pharmacol, 2001. 51(1): p. 87–91.PubMedGoogle Scholar
  34. 34.
    Wolff, A.J. and A.E. O’Donnell, Pulmonary effects of illicit drug use. Clin Chest Med, 2004. 25(1): p. 203–16.PubMedGoogle Scholar
  35. 35.
    Han, B., J.C. Gfroerer, and J.D. Colliver, Associations between duration of illicit drug use and health conditions: results from the 2005–2007 national surveys on drug use and health. Ann Epidemiol, 2010. 20(4): p. 289–97.PubMedGoogle Scholar
  36. 36.
    Weitzman, J.B., N.F. Kanarek, and J.E. Smialek, Medical examiner asthma death autopsies: a distinct subgroup of asthma deaths with implications for public health preventive strategies. Arch Pathol Lab Med, 1998. 122(8): p. 691–9.PubMedGoogle Scholar
  37. 37.
    Levenson, T., et al., Asthma deaths confounded by substance abuse. An assessment of fatal asthma. Chest, 1996. 110(3): p. 604–10.PubMedGoogle Scholar
  38. 38.
    Merigian, K. and K. Blaho, The role of pharmacology and forensics in the death of an asthmatic. J Anal Toxicol, 1995. 19(6): p. 522–8.PubMedGoogle Scholar
  39. 39.
    Waldbott, G.L., Asthma due to a local anesthetic. J Am Med Assoc, 1932. 99(23): p. 1942.Google Scholar
  40. 40.
    Weiss, K.B., P.J. Gergen, and E.F. Crain, Inner-city asthma. The epidemiology of an emerging US public health concern. Chest, 1992. 101(6 Suppl): p. 362 S–367 S.PubMedGoogle Scholar
  41. 41.
    Greenberger, P.A., T.P. Miller, and B. Lifschultz, Circumstances surrounding deaths from asthma in Cook County (Chicago) Illinois. Allergy Proc, 1993. 14(5): p. 321–6.PubMedGoogle Scholar
  42. 42.
    Osborn, H.H., et al., New-onset bronchospasm or recrudescence of asthma associated with cocaine abuse. Acad Emerg Med, 1997. 4(7): p. 689–92.PubMedGoogle Scholar
  43. 43.
    Panacek, E.A., et al., Is unexplained bronchospasm associated with the use of cocaine (abstract)? Ann Emerg Med, 1991. 20 (suppl): p. 488–489.Google Scholar
  44. 44.
    Rome, L.A., et al., Prevalence of cocaine use and its impact on asthma exacerbation in an urban population. Chest, 2000. 117(5): p. 1324–9.PubMedGoogle Scholar
  45. 45.
    Rubin, R.B. and J. Neugarten, Cocaine-associated asthma. Am J Med, 1990. 88(4): p. 438–9.PubMedGoogle Scholar
  46. 46.
    Rebhun, J., Association of asthma and freebase smoking. Ann Allergy, 1988. 60(4): p. 339–42.PubMedGoogle Scholar
  47. 47.
    Rao, A.N., P.G. Polos, and F.A. Walther, Crack abuse and asthma: a fatal combination. N Y State J Med, 1990. 90(10): p. 511–2.PubMedGoogle Scholar
  48. 48.
    Levine, M., et al., The effects of cocaine and heroin use on intubation rates and hospital utilization in patients with acute asthma exacerbations. Chest, 2005. 128(4): p. 1951–7.PubMedGoogle Scholar
  49. 49.
    Averbach, M., K.K. Casey, and E. Frank, Near-fatal status asthmaticus induced by nasal insufflation of cocaine. South Med J, 1996. 89(3): p. 340–1.PubMedGoogle Scholar
  50. 50.
    Meisels, I.S. and J. Loke, The pulmonary effects of free-base cocaine: a review. Cleve Clin J Med, 1993. 60(4): p. 325–9.PubMedGoogle Scholar
  51. 51.
    Dean, N.C., et al., Pulmonary function in heavy users of ‘freebase’ cocaine (abstr) Am Rev Respir Dis, 1988. 137 S: p. 489.Google Scholar
  52. 52.
    Weiss, R.D., et al., Pulmonary dysfunction in cocaine smokers. Am J Psychiatry, 1981. 138(8): p. 1110–2.PubMedGoogle Scholar
  53. 53.
    Weiss, R.D., et al., Decreased single breath carbon monoxide diffusing capacity in cocaine freebase smokers. Drug Alcohol Depend, 1987. 19(3): p. 271–6.PubMedGoogle Scholar
  54. 54.
    Susskind, H., et al., Increased lung permeability following long-term use of free-base cocaine (crack). Chest, 1991. 100(4): p. 903–9.PubMedGoogle Scholar
  55. 55.
    Itkonen, J., S. Schnoll, and J. Glassroth, Pulmonary dysfunction in ‘freebase’ cocaine users. Arch Intern Med, 1984. 144(11): p. 2195–7.PubMedGoogle Scholar
  56. 56.
    Tashkin, D.P., Airway effects of marijuana, cocaine, and other inhaled illicit agents. Curr Opin Pulm Med, 2001. 7(2): p. 43–61.PubMedGoogle Scholar
  57. 57.
    Tashkin, D.P., et al., Acute effects of inhaled and i.v. cocaine on airway dynamics. Chest, 1996. 110(4): p. 904–10.Google Scholar
  58. 58.
    Kissner, D.G., et al., Crack lung: pulmonary disease caused by cocaine abuse. Am Rev Respir Dis, 1987. 136(5): p. 1250–2.PubMedGoogle Scholar
  59. 59.
    Kikuchi, Y., et al., Chemosensitivity and perception of dyspnea in patients with a history of near-fatal asthma. N Engl J Med, 1994. 330(19): p. 1329–34.PubMedGoogle Scholar
  60. 60.
    Zaas, D., et al., An uncommon mimic of an acute asthma exacerbation. Chest, 2002. 121(5): p. 1707–9.PubMedGoogle Scholar
  61. 61.
    Dowling, G.P., E.T. McDonough, III, and R.O. Bost, ‘Eve’ and ‘Ecstasy’. A report of five deaths associated with the use of MDEA and MDMA. JAMA, 1987. 257(12): p. 1615–7.PubMedGoogle Scholar
  62. 62.
    Saito, T., et al., Determination of chronic methamphetamine abuse by hair analysis. Forensic Sci Int, 2000. 112(1): p. 65–71.PubMedGoogle Scholar
  63. 63.
    Schmidt, R.A., et al., Panlobular emphysema in young intravenous Ritalin abusers. Am Rev Respir Dis, 1991. 143(3): p. 649–56.PubMedGoogle Scholar
  64. 64.
    Sherman, C.B., L.D. Hudson, and D.J. Pierson, Severe precocious emphysema in intravenous methylphenidate (Ritalin) abusers. Chest, 1987. 92(6): p. 1085–7.PubMedGoogle Scholar
  65. 65.
    del los Santos-Sastre, S., F. Capote-Gil, and A. Gonzales-Castro, Airway obstruction and heroin ­inhalation. Lancet, 1986. 2(8516): p. 1158.Google Scholar
  66. 66.
    Oliver, R.M., Bronchospasm and heroin inhalation. Lancet, 1986. 1(8486): p. 915.PubMedGoogle Scholar
  67. 67.
    Anderson, K., Bronchospasm and intravenous street heroin. Lancet, 1986. 1(8491): p. 1208.PubMedGoogle Scholar
  68. 68.
    Hughes, S. and P.M. Calverley, Heroin inhalation and asthma. BMJ, 1988. 297(6662): p. 1511–2.PubMedGoogle Scholar
  69. 69.
    Sapira, J.D., The narcotic addict as a medical patient. Am J Med, 1968. 45(4): p. 555–88.PubMedGoogle Scholar
  70. 70.
    Ghodse, A.H. and J.S. Myles, Asthma in opiate addicts. J Psychosom Res, 1987. 31(1): p. 41–4.PubMedGoogle Scholar
  71. 71.
    Cruz, R., et al., Pulmonary manifestations of inhaled street drugs. Heart Lung, 1998. 27(5): p. 297–305; quiz 306–7.Google Scholar
  72. 72.
    Brander, P.E. and P. Tukiainen, Acute eosinophilic pneumonia in a heroin smoker. Eur Respir J, 1993. 6(5): p. 750–2.PubMedGoogle Scholar
  73. 73.
    Cygan, J., M. Trunsky, and T. Corbridge, Inhaled heroin-induced status asthmaticus: five cases and a review of the literature. Chest, 2000. 117(1): p. 272–5.PubMedGoogle Scholar
  74. 74.
    Spiritus, E.M., A.F. Wilson, and R.A. Berke, Lung scans in asymptomatic heroin addicts. Am Rev Respir Dis, 1973. 108(4): p. 994–6.PubMedGoogle Scholar
  75. 75.
    Camargo, G. and C. Colp, Pulmonary function studies in ex-heroin users. Chest, 1975. 67(3): p. 331–4.PubMedGoogle Scholar
  76. 76.
    Overland, E.S., A.J. Nolan, and P.C. Hopewell, Alteration of pulmonary function in intravenous drug abusers. Prevalence, severity, and characterization of gas exchange abnormalities. Am J Med, 1980. 68(2): p. 231–7.PubMedGoogle Scholar
  77. 77.
    Krantz, A.J., et al., Heroin insufflation as a trigger for patients with life-threatening asthma. Chest, 2003. 123(2): p. 510–7.PubMedGoogle Scholar
  78. 78.
    Eschenbacher, W.L., et al., Morphine sulfate inhibits bronchoconstriction in subjects with mild asthma whose responses are inhibited by atropine. Am Rev Respir Dis, 1984. 130(3): p. 363–7.PubMedGoogle Scholar
  79. 79.
    Mestiri, M., et al., Effect of inhaled morphine on the bronchial response to isocapnic hyperventilation in patients with allergic asthma. Eur J Clin Pharmacol, 1991. 41(6): p. 621.PubMedGoogle Scholar
  80. 80.
    Field, P.I., et al., Evidence for opioid modulation and generation of prostaglandins in sulphur dioxide (SO)2-induced bronchoconstriction. Thorax, 1996. 51(2): p. 159–63.PubMedGoogle Scholar
  81. 81.
    Ulinski, S., C. Palczynski, and P. Gorski, Occupational rhinitis and bronchial asthma due to morphine: evidence from inhalational and nasal challenges. Allergy, 1996. 51(12): p. 914–8.PubMedGoogle Scholar
  82. 82.
    Biagini, R.E., et al., Antibodies to morphine in workers exposed to opiates at a narcotics manufacturing facility and evidence for similar antibodies in heroin abusers. Life Sci, 1990. 47(10): p. 897–908.PubMedGoogle Scholar
  83. 83.
    Tashkin, D.P., et al., Respiratory and immunologic consequences of marijuana smoking. J Clin Pharmacol, 2002. 42(11 Suppl): p. 71 S–81 S.PubMedGoogle Scholar
  84. 84.
    Tashkin, D.P., B.J. Shapiro, and I.M. Frank, Acute effects of smoked marijuana and oral delta9-­tetrahydrocannabinol on specific airway conductance in asthmatic subjects. Am Rev Respir Dis, 1974. 109(4): p. 420–8.PubMedGoogle Scholar
  85. 85.
    Tashkin, D.P., et al., Respiratory symptoms and lung function in habitual heavy smokers of marijuana alone, smokers of marijuana and tobacco, smokers of tobacco alone, and nonsmokers. Am Rev Respir Dis, 1987. 135(1): p. 209–16.PubMedGoogle Scholar
  86. 86.
    Bloom, J.W., et al., Respiratory effects of non-tobacco cigarettes. Br Med J (Clin Res Ed), 1987. 295(6612): p. 1516–8.Google Scholar
  87. 87.
    Taylor, D.R., et al., The respiratory effects of cannabis dependence in young adults. Addiction, 2000. 95(11): p. 1669–77.PubMedGoogle Scholar
  88. 88.
    Friedman, H., et al., Marijuana, receptors and immunomodulation. Adv Exp Med Biol, 1995. 373: p. 103–13.PubMedGoogle Scholar
  89. 89.
    Specter, S.C., et al., Marijuana effects on immunity: suppression of human natural killer cell activity of delta-9-tetrahydrocannabinol. Int J Immunopharmacol, 1986. 8(7): p. 741–5.PubMedGoogle Scholar
  90. 90.
    Anonymous. Tobacco use and usual source of cigarettes among high school students--United States, 1995. MMWR Morb Mortal Wkly Rep, 1996. 45(20): p. 413–8.Google Scholar
  91. 91.
    Anonymous. Prevalence of cigarette use among 14 racial/ethnic populations--United States, 1999–2001. MMWR Morb Mortal Wkly Rep, 2004. 53(3): p. 49–52.Google Scholar
  92. 92.
    Anon. Cigarette smoking and health. American Thoracic Society. Am J Respir Crit Care Med, 1996. 153(2): p. 861–5.Google Scholar
  93. 93.
    Benowitz, N.L., Nicotine addiction. N Engl J Med, 2010. 362(24): p. 2295–303.PubMedGoogle Scholar
  94. 94.
    Willers, S., E. Svenonius, and G. Skarping, Passive smoking and childhood asthma. Urinary cotinine levels in children with asthma and in referents. Allergy, 1991. 46(5): p. 330–4.PubMedGoogle Scholar
  95. 95.
    Cunningham, J., D.W. Dockery, and F.E. Speizer, Maternal smoking during pregnancy as a predictor of lung function in children. Am J Epidemiol, 1994. 139(12): p. 1139–52.PubMedGoogle Scholar
  96. 96.
    Weiss, S.T., Environmental risk factors in childhood asthma. Clin Exp Allergy, 1998. 28 Suppl 5: p. 29–34; discussion 50–1.PubMedGoogle Scholar
  97. 97.
    Annesi-Maesano, I., et al., Increased prevalence of asthma and allied diseases among active adolescent tobacco smokers after controlling for passive smoking exposure. A cause for concern? Clin Exp Allergy, 2004. 34(7): p. 1017–23.PubMedGoogle Scholar
  98. 98.
    Jang, A.S., et al., The effect of passive smoking on asthma symptoms,atopy,and airway hyperresponsiveness in schoolchildren. J Korean Med Sci, 2004. 19(2): p. 214–7.PubMedGoogle Scholar
  99. 99.
    Janson, C., The effect of passive smoking on respiratory health in children and adults. Int J Tuberc Lung Dis, 2004. 8(5): p. 510–6.PubMedGoogle Scholar
  100. 100.
    LeSon, S. and M.E. Gershwin, Risk factors for asthmatic patients requiring intubation. I. Observations in children. J Asthma, 1995. 32(4): p. 285–94.PubMedGoogle Scholar
  101. 101.
    Eisner, M.D., et al., Environmental tobacco smoke and adult asthma. The impact of changing exposure status on health outcomes. Am J Respir Crit Care Med, 1998. 158(1): p. 170–5.PubMedGoogle Scholar
  102. 102.
    Flodin, U., et al., An epidemiologic study of bronchial asthma and smoking. Epidemiology, 1995. 6(5): p. 503–5.PubMedGoogle Scholar
  103. 103.
    White, J.R. and H.F. Froeb, Small-airways dysfunction in nonsmokers chronically exposed to tobacco smoke. N Engl J Med, 1980. 302(13): p. 720–3.PubMedGoogle Scholar
  104. 104.
    Schwartz, J., K.L. Timonen, and J. Pekkanen, Respiratory effects of environmental tobacco smoke in a panel study of asthmatic and symptomatic children. Am J Respir Crit Care Med, 2000. 161(3 Pt 1): p. 802–6.PubMedGoogle Scholar
  105. 105.
    Lubman, D.I., M. Yucel, and A.J. Lawrence, Inhalant abuse among adolescents: neurobiological considerations. Br J Pharmacol, 2008. 154(2): p. 316–26.PubMedGoogle Scholar
  106. 106.
    Chadwick, O., et al., Neuropsychological consequences of volatile substance abuse: a population based study of secondary school pupils. BMJ, 1989. 298(6689): p. 1679–84.PubMedGoogle Scholar
  107. 107.
    Wu, L.T., D.J. Pilowsky, and W.E. Schlenger, Inhalant abuse and dependence among adolescents in the United States. J Am Acad Child Adolesc Psychiatry, 2004. 43(10): p. 1206–14.PubMedGoogle Scholar
  108. 108.
    Schikler, K.N., et al., Solvent abuse associated pulmonary abnormalities. Adv Alcohol Subst Abuse, 1984. 3(3): p. 75–81.PubMedGoogle Scholar
  109. 109.
    Meredith, T.J., et al., Diagnosis and treatment of acute poisoning with volatile substances. Hum Toxicol, 1989. 8(4): p. 277–286.PubMedGoogle Scholar
  110. 110.
    Cartwright, T.R., E.D. Brown, and R.E. Brashear, Pulmonary infiltrates following butane ‘fire-breathing’. Arch Intern Med, 1983. 143(10): p. 2007–8.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Timothy E. Albertson
    • 1
    • 2
  • Kelly P. Owen
    • 3
    • 2
  • Mark E. Sutter
    • 4
  • Nicholas J. Kenyon
    • 1
    • 5
    • 2
  1. 1.Division of Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine and Department of Emergency MedicineUniversity of California at DavisSacramentoUSA
  2. 2.VA Northern California Health Care SystemMatherUSA
  3. 3.Department of Emergency MedicineUniversity of California at Davis, Sacramento Medical CenterSacramentoUSA
  4. 4.Department of Emergency MedicineUniversity of California at DavisSacramentoUSA
  5. 5.UC Davis Center for Comparative Respiratory Biology and MedicineDavisUSA

Personalised recommendations